Elanco Animal Health (NYSE:ELAN) Releases Earnings Results, Beats Expectations By $0.08 EPS

Elanco Animal Health (NYSE:ELAN) released its quarterly earnings results on Wednesday. The company reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.26 by $0.08, Briefing.com reports. The company had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.18 billion. Elanco Animal Health had a positive return on equity of 6.44% and a negative net margin of 27.87%. Elanco Animal Health’s revenue was down 4.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.45 earnings per share.

Elanco Animal Health Stock Performance

ELAN stock traded up $0.31 during mid-day trading on Thursday, hitting $17.21. 7,407,675 shares of the company were exchanged, compared to its average volume of 4,585,274. Elanco Animal Health has a 1-year low of $7.88 and a 1-year high of $17.43. The business has a 50 day simple moving average of $14.98 and a 200-day simple moving average of $14.04. The company has a current ratio of 2.75, a quick ratio of 1.35 and a debt-to-equity ratio of 0.92. The stock has a market capitalization of $8.50 billion, a PE ratio of -6.79, a price-to-earnings-growth ratio of 1.42 and a beta of 1.34.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Morgan Stanley raised their price target on Elanco Animal Health from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 27th. Barclays boosted their target price on Elanco Animal Health from $19.00 to $23.00 and gave the company an “overweight” rating in a research note on Thursday. The Goldman Sachs Group raised their price target on shares of Elanco Animal Health from $12.50 to $14.00 and gave the stock a “sell” rating in a research note on Tuesday, February 27th. Finally, TheStreet raised shares of Elanco Animal Health from a “d+” rating to a “c-” rating in a research report on Friday, February 23rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Elanco Animal Health currently has an average rating of “Moderate Buy” and a consensus target price of $17.29.

Insiders Place Their Bets

In other Elanco Animal Health news, Director R David Hoover purchased 20,000 shares of the stock in a transaction dated Wednesday, March 6th. The stock was bought at an average price of $16.14 per share, with a total value of $322,800.00. Following the acquisition, the director now owns 185,000 shares of the company’s stock, valued at $2,985,900. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.57% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.